Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs

References

• Fink K, Boratyński J. Rola metaloproteinaz w modyfikacji macierzy zewnątrzkomórkowej w nowotworowym wzroście inwazyjnym, w przerzutowaniu i w angiogenezie. Post Hig Med Dosw 2012;66:609–28.
   Web of Science ®Google Scholar
• Ricard-Blum S, Ruggiero F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol (Paris) 2005;53:430–42.
   PubMed Web of Science ®Google Scholar
• Heino J. The collagen family members as cell adhesion proteins. Bioessays 2007;29:1001–10.
   PubMed Web of Science ®Google Scholar
• Gelse K, Pöschl E, Aigner T. Collagens – structure, function, and biosynthesis. Adv Drug Deliv Rev 2003;55:1531–46.
   PubMed Web of Science ®Google Scholar
• Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet 2004;20:33–43.
   PubMed Web of Science ®Google Scholar
• Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562–73.
   PubMed Web of Science ®Google Scholar
• Bogaczewicz J, Sysa-Jedrzejowska A, Woźniacka A. Role of matrix metalloproteinases in primary systemic vasculitis. Pol Merkur Lekarski 2008;24:85–9.
   PubMedGoogle Scholar
• Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962;48:1014–22.
   PubMed Web of Science ®Google Scholar
• Hrabec E, Naduk J, Strek M, Hrabec Z. Type IV collagenases (MMP-2 and MMP-9) and their substrates–intracellular proteins, hormones, cytokines, chemokines and their receptors. Post Biochem 2007;53:37–45.
   PubMedGoogle Scholar
• Yadav L, Puri N, Rastogi V, et al Matrix metalloproteinases and cancer – roles in threat and therapy. Asian Pac J Cancer Prev 2014;15:1085–91.
   PubMedGoogle Scholar
• Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011;278:16–27.
   PubMed Web of Science ®Google Scholar
• Rogowicz A, Zozulińska D, Wierusz-Wysocka B. The role of matrix metalloproteinases in the development of vascular complications of diabetes mellitus–clinical implications. Pol Arch Med Wewn 2007;117:43–8.
   PubMedGoogle Scholar
• Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005;5:285–98.
   PubMed Web of Science ®Google Scholar
• Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260–70.
   PubMed Web of Science ®Google Scholar
• Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008;19:52–60.
   PubMed Web of Science ®Google Scholar
• Maretzky T, Reiss K, Ludwig A, et al ADAM-10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration and beta-catenin translocation. Proc Natl Acad Sci USA 2005;102:9182–7.
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–74.
   PubMed Web of Science ®Google Scholar
• Rozanov VD, Hahn-Dantona E, Strickland DK, Strongin AY. The low-density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J Biol Chem 2004;279:4260–8.
   PubMed Web of Science ®Google Scholar
• Krzyżanowska-Gołąb D, Lemańska-Perek A, Kątnik-Prastowska I. Fibronektyna jako aktywny składnik macierzy pozakomórkowej. Post Hig Med Dośw 2007;61:655–63.
   Google Scholar
• Ungefroren H, Sebens S, Seidl D, et al Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011;9:18. doi: 10.1186/1478-811X-9-18.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52–67.
   PubMed Web of Science ®Google Scholar
• Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010;20:161–8.
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Cell surface-localized matrix metalloprote inase-9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes Dev 2000;14:163–76.
   PubMed Web of Science ®Google Scholar
• Gialeli C, Kletsas D, Mavroudis D, et al Targeting epidermal growth factor receptor in solid tumours: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr Med Chem 2009;16:3797–804.
   PubMed Web of Science ®Google Scholar
• Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 2013;1833:3481–98.
   PubMed Web of Science ®Google Scholar
• Rundhaung JE. Matrix metalloproteinases, angiogenesis and cancer. Clin Cancer Res 2003;9:551–4.
   PubMed Web of Science ®Google Scholar
• Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta 2010;1803:103–20.
   PubMed Web of Science ®Google Scholar
• Hangai M, Kitaya N, Xu J, et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am J Pathol 2002;161:1429–37.
   PubMed Web of Science ®Google Scholar
• Sounni N, Paye A, Host L, Noël A. MT-MMPs as regulators of vessel stability associated with angiogenesis. Front Pharmacol 2011;2:111. doi: 10.3389/fphar.2011.00111.
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002;3:509–19.
   PubMed Web of Science ®Google Scholar
• Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128–37.
   PubMedGoogle Scholar
• Thiery JP. Epithelial mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442–54.
   PubMed Web of Science ®Google Scholar
• Illman SA, Lehti K, Keski-Oja J, Lohi J. Epilysin(MMP-28) induces TGF B mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 2006;119:3856–65.
   PubMed Web of Science ®Google Scholar
• Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5:203–20.
   PubMed Web of Science ®Google Scholar
• Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new function to improved inhibition strategies. Int J Dev Biol 2004;48:411–24.
   PubMed Web of Science ®Google Scholar
• Karin M, Chang L. AP-1 glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol 2001;169:447–51.
   PubMed Web of Science ®Google Scholar
• Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157–66.
   PubMed Web of Science ®Google Scholar
• Yan YL, Miller MT, Cao Y, Cohen SM. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett 2009;19:1970–6.
   PubMed Web of Science ®Google Scholar
• Chaudhary AK, Singh M, Bharti AC, et al. Genetic polymorphism of matrix metalloproteinases and their inhibitors in potentially malignant lesions of the head and neck. J Biomed Sci 2010;17:10. doi: 10.1186/1423-0127-17-10.
   PubMed Web of Science ®Google Scholar
• Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258–65.
   PubMed Web of Science ®Google Scholar
• Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006;6:307–12.
   PubMed Web of Science ®Google Scholar
• Mitropoulou TN, Tzanakakis GN, Kletsas D, et al Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer 2003;104:155–60.
   PubMed Web of Science ®Google Scholar
• Falardeau P, Champagne P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001;28:620–5.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen S, Xu L, et al Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005;65:3470–8.
   PubMed Web of Science ®Google Scholar
• Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on Batimastat and Marimastat. Pharmacol Ther 1997;75:69–75.
   PubMed Web of Science ®Google Scholar
• Wang A, Stout D, Zhang Q, Johnson EF. Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding. J Biol Chem 2015;290:5092–104.
   PubMed Web of Science ®Google Scholar
• Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006;25:115–36.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014;13:904–27.
   PubMed Web of Science ®Google Scholar